Cryptococcal Meningitis

Cryptococcus neoformans infection begins when aerosolized desiccated yeast cells or spores are inhaled from environmental sources, such as aged pigeon droppings. The spores survive in lung alveoli, where they can remain extracellular or be phagocytosed by alveolar macrophages, initiating pulmonary colonization and potential hematogenous dissemination.

Cryptococcus neoformans expresses two major virulence factors: a polysaccharide capsule that inhibits phagocytosis and promotes immune evasion, and melanin, which protects against oxidative stress and binds to antifungal agents, reducing the pathogen's susceptibility to drugs.

After multiplying inside macrophages and spreading through the bloodstream, Cryptococcus neoformans produces enzymes like metalloproteinases and urease that increase blood-brain barrier permeability. These enzymes facilitate the fungus's invasion of the central nervous system and subsequent multiplication in cerebrospinal fluid.

Cryptococcal meningitis causes inflammation of the meninges and obstruction of cerebrospinal fluid outflow, leading to increased intracranial pressure. Patients experience persistent headache, fever, visual disturbances, altered mental status, photophobia, and potentially cranial neuropathies, with presentations often subtle in immunocompromised individuals.

Cryptococcal meningitis predominantly affects immunocompromised individuals, including HIV/AIDS patients, those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection accounts for over 100,000 deaths annually worldwide, particularly in resource-limited settings.

Diagnosis relies on cerebrospinal fluid analysis, including cryptococcal antigen testing, India ink staining, and culture. Elevated cerebrospinal fluid opening pressure is a critical prognostic marker requiring frequent monitoring to assess disease severity and guide management of increased intracranial pressure.

Treatment involves a three-phase antifungal regimen: induction with amphotericin B combined with flucytosine, consolidation with fluconazole, and maintenance therapy to prevent relapse. Resource-limited settings often modify this approach due to flucytosine unavailability, requiring interprofessional collaboration to optimize patient outcomes.